Prestige Consumer Q1 revenue $267.1M beats expectations; reaffirms FY2025 outlook

Prestige Consumer Healthcare Inc.

2025-Q1 EPS reported $0.98 revenue$267,142,000

Q1 GAAP EPS $0.98, adjusted EPS $0.90; revenue down 4.4% YoY but ahead of internal plan.
Cash from operations $54.8M (+13.9% YoY); reduced debt $35M and repurchased $26M in shares.
North American OTC revenue $232.3M (-5.6%); International OTC $34.8M (+5.0% driven by Hydralyte).
FY2025 guidance reaffirmed: revenue $1.125-$1.140B, adjusted EPS $4.40-$4.46, FCF $240M+.
CEO cited earlier supply of Clear Eyes products as primary driver of Q1 beat over expectations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.